<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33589474</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><Issue>5</Issue><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Value of systematic genetic screening of patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>510</StartPage><EndPage>518</EndPage><MedlinePgn>510-518</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2020-325014</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The clinical utility of routine genetic sequencing in amyotrophic lateral sclerosis (ALS) is uncertain. Our aim was to determine whether routine targeted sequencing of 44 ALS-relevant genes would have a significant impact on disease subclassification and clinical care.</AbstractText><AbstractText Label="METHODS">We performed targeted sequencing of a 44-gene panel in a prospective case series of 100 patients with ALS recruited consecutively from the Sheffield Motor Neuron Disorders Clinic, UK. All participants were diagnosed with ALS by a specialist Consultant Neurologist. 7/100 patients had familial ALS, but the majority were apparently sporadic cases.</AbstractText><AbstractText Label="RESULTS">21% of patients with ALS carried a confirmed pathogenic or likely pathogenic mutation, of whom 93% had no family history of ALS. 15% met the inclusion criteria for a current ALS genetic-therapy trial. 5/21 patients with a pathogenic mutation had an additional variant of uncertain significance (VUS). An additional 21% of patients with ALS carried a VUS in an ALS-associated gene. Overall, 13% of patients carried more than one genetic variant (pathogenic or VUS). Patients with ALS carrying two variants developed disease at a significantly earlier age compared with patients with a single variant (median age of onset=56 vs 60 years, p=0.0074).</AbstractText><AbstractText Label="CONCLUSIONS">Routine screening for ALS-associated pathogenic mutations in a specialised ALS referral clinic will impact clinical care in 21% of cases. An additional 21% of patients have variants in the ALS gene panel currently of unconfirmed significance after removing non-specific or predicted benign variants. Overall, variants within known ALS-linked genes are of potential clinical importance in 42% of patients.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Shepheard</LastName><ForeName>Stephanie R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0002-2358-7348</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Parker</LastName><ForeName>Matthew D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cooper-Knock</LastName><ForeName>Johnathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0873-8689</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verber</LastName><ForeName>Nick S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuddenham</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heath</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beauchamp</LastName><ForeName>Nick</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Human Genetics, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Place</LastName><ForeName>Elsie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Human Genetics, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sollars</LastName><ForeName>Elizabeth S A</ForeName><Initials>ESA</Initials><AffiliationInfo><Affiliation>Human Genetics, Sheffield Children's Hospital NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuroscience and Trauma, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fratta</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neuromuscular Diseases, University College London Institute of Neurology, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hewamadduma</LastName><ForeName>Channa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Academic Directorate of Neuroscience, Department of Clinical Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><Identifier Source="ORCID">0000-0003-0342-7184</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirby</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Academic Directorate of Neuroscience, Department of Clinical Neurology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Project MINE Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Project MinE</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/M008606/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R56 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NECTAR/OCT15/974-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>FRATTA/JAN15/946-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TURNER/OCT15/972-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S006508/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="Y">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: None declared.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Blair</LastName><ForeName>Ian</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitne Neto</LastName><ForeName>Miguel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chio</LastName><ForeName>Adriano</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cauchi</LastName><ForeName>Ruben</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLaughin</LastName><ForeName>Russell</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivian</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Veldink</LastName><ForeName>Jan H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mora Pardina</LastName><ForeName>Jesus S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weber</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ba Ak</LastName><ForeName>Nazli A</ForeName><Initials>NA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornsetin</LastName><ForeName>Eran</ForeName><Initials>E</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33589474</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pii">jnnp-2020-325014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Strong MJ, Grace GM, Freedman M, et al. . Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009;10:131&#x2013;46. 10.1080/17482960802654364</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802654364</ArticleId><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014;17:17&#x2013;23. 10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pmc">PMC4544832</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, et al. . Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 2012;135:751&#x2013;64. 10.1093/brain/awr365</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr365</ArticleId><ArticleId IdType="pmc">PMC3286332</ArticleId><ArticleId IdType="pubmed">22366792</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. . A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257&#x2013;68. 10.1016/j.neuron.2011.09.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller K, Brenner D, Weydt P, et al. . Comprehensive analysis of the mutation spectrum in 301 German ALS families. J Neurol Neurosurg Psychiatry 2018;89:817&#x2013;27. 10.1136/jnnp-2017-317611</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317611</ArticleId><ArticleId IdType="pubmed">29650794</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59&#x2013;62. 10.1038/362059a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al. . TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008;40:572&#x2013;4. 10.1038/ng.132</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.132</ArticleId><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al. . TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668&#x2013;72. 10.1126/science.1154584</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortob&#xe1;gyi T, et al. . Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009;323:1208&#x2013;11. 10.1126/science.1165942</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Allred P, Bali T, et al. . Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol 2015;77:100&#x2013;13. 10.1002/ana.24306</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24306</ArticleId><ArticleId IdType="pmc">PMC4293318</ArticleId><ArticleId IdType="pubmed">25382069</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann EP, Henden L, Fifita JA, et al. . Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. J Med Genet 2020:jmedgenet-2020-106866. 10.1136/jmedgenet-2020-106866</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2020-106866</ArticleId><ArticleId IdType="pubmed">32409511</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 2014;13:1108&#x2013;13. 10.1016/S1474-4422(14)70219-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Logroscino G, Hardiman O, et al. . Prognostic factors in ALS: a critical review. Amyotrophic Lateral Sclerosis 2008:1&#x2013;14. 10.1080/17482960802566824</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802566824</ArticleId><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Al-Chalabi A, Chio A, et al. . Genetic screening in sporadic ALS and FTD. J Neurol Neurosurg Psychiatry 2017;88:1042&#x2013;4. 10.1136/jnnp-2017-315995</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-315995</ArticleId><ArticleId IdType="pmc">PMC5740553</ArticleId><ArticleId IdType="pubmed">28642287</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012:CD001447. 10.1002/14651858.CD001447.pub3</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pubmed">11687111</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotrophic Lateral Sclerosis 2006;7:247&#x2013;51. 10.1080/17482960600881870</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone ER, Oliva M, Sabatini PJB, et al. . Molecular profiling for precision cancer therapies. Genome Med 2020;12:8. 10.1186/s13073-019-0703-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-019-0703-1</ArticleId><ArticleId IdType="pmc">PMC6961404</ArticleId><ArticleId IdType="pubmed">31937368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W, Shatunov A, Stahl D, et al. . ATXN2 trinucleotide repeat length correlates with risk of ALS. Neurobiol Aging 2017;51:178.e1&#x2013;9. 10.1016/j.neurobiolaging.2016.11.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.11.010</ArticleId><ArticleId IdType="pmc">PMC5302215</ArticleId><ArticleId IdType="pubmed">28017481</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009;25:1754&#x2013;60. 10.1093/bioinformatics/btp324</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btp324</ArticleId><ArticleId IdType="pmc">PMC2705234</ArticleId><ArticleId IdType="pubmed">19451168</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenna A, Hanna M, Banks E, et al. . The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297&#x2013;303. 10.1101/gr.107524.110</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.107524.110</ArticleId><ArticleId IdType="pmc">PMC2928508</ArticleId><ArticleId IdType="pubmed">20644199</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan A, Abecasis GR, Kang HM. Unified representation of genetic variants. Bioinformatics 2015;31:2202&#x2013;4. 10.1093/bioinformatics/btv112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btv112</ArticleId><ArticleId IdType="pmc">PMC4481842</ArticleId><ArticleId IdType="pubmed">25701572</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et al. . Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. BioRxiv 2019.</Citation></Reference><Reference><Citation>Schwarz JM, R&#xf6;delsperger C, Schuelke M, et al. . MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010;7:575&#x2013;6. 10.1038/nmeth0810-575</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0810-575</ArticleId><ArticleId IdType="pubmed">20676075</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA, Schmidt S, Peshkin L, et al. . A method and server for predicting damaging missense mutations. Nat Methods 2010;7:248&#x2013;9. 10.1038/nmeth0410-248</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth0410-248</ArticleId><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812&#x2013;4. 10.1093/nar/gkg509</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkg509</ArticleId><ArticleId IdType="pmc">PMC168916</ArticleId><ArticleId IdType="pubmed">12824425</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper GM, Stone EA, Asimenos G, et al. . Distribution and intensity of constraint in mammalian genomic sequence. Genome Res 2005;15:901&#x2013;13. 10.1101/gr.3577405</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.3577405</ArticleId><ArticleId IdType="pmc">PMC1172034</ArticleId><ArticleId IdType="pubmed">15965027</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzsch P, Witten D, Cooper GM, et al. . CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res 2019;47:D886&#x2013;94. 10.1093/nar/gky1016</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky1016</ArticleId><ArticleId IdType="pmc">PMC6323892</ArticleId><ArticleId IdType="pubmed">30371827</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese MG, Eeckman FH, Kulp D, et al. . Improved splice site detection in genie. J Comput Biol 1997;4:311&#x2013;23. 10.1089/cmb.1997.4.311</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/cmb.1997.4.311</ArticleId><ArticleId IdType="pubmed">9278062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pertea M, Lin X, Salzberg SL. GeneSplicer: a new computational method for splice site prediction. Nucleic Acids Res 2001;29:1185&#x2013;90. 10.1093/nar/29.5.1185</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/29.5.1185</ArticleId><ArticleId IdType="pmc">PMC29713</ArticleId><ArticleId IdType="pubmed">11222768</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo G, Burge CB. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 2004;11:377&#x2013;94. 10.1089/1066527041410418</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/1066527041410418</ArticleId><ArticleId IdType="pubmed">15285897</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Riley GR, et al. . ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res 2014;42:D980&#x2013;5. 10.1093/nar/gkt1113</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1113</ArticleId><ArticleId IdType="pmc">PMC3965032</ArticleId><ArticleId IdType="pubmed">24234437</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellard S, Lindsay H, Camm N, et al. . Practice guidelines for targeted next generation sequencing analysis and interpretation. ACGS Best Practice Guidelines 2014.</Citation></Reference><Reference><Citation>Osmanovic A, Rangnau I, Kosfeld A, et al. . FIG4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study. Eur J Hum Genet 2017;25:324&#x2013;31. 10.1038/ejhg.2016.186</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ejhg.2016.186</ArticleId><ArticleId IdType="pmc">PMC5315518</ArticleId><ArticleId IdType="pubmed">28051077</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Hentati A, Deng HX, et al. . The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001;29:160&#x2013;5. 10.1038/ng1001-160</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1001-160</ArticleId><ArticleId IdType="pubmed">11586297</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium . Project mine: study design and pilot analyses of a large-scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet 2018;26:1537&#x2013;46. 10.1038/s41431-018-0177-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-018-0177-4</ArticleId><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al. . Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat Neurosci 2015;18:631&#x2013;6. 10.1038/nn.4000</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Robins H, Niedermoser I, et al. . Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front Mol Neurosci 2017;10:370. 10.3389/fnmol.2017.00370</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00370</ArticleId><ArticleId IdType="pmc">PMC5684183</ArticleId><ArticleId IdType="pubmed">29170628</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesiridis GS, Lee VM-Y, Trojanowski JQ. Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis. Hum Mol Genet 2009;18:R156&#x2013;62. 10.1093/hmg/ddp303</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp303</ArticleId><ArticleId IdType="pmc">PMC2758707</ArticleId><ArticleId IdType="pubmed">19808791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, van Doormaal PTC, Dekker AM, et al. . NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 2016;48:1037&#x2013;42. 10.1038/ng.3626</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, van Es MA, Hennekam EAM, et al. . Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 2012;21:3776&#x2013;84. 10.1093/hmg/dds199</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds199</ArticleId><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>